Introduction And Epidemiology

• Acute self-limited systemic vasculitis.
• Primarily affects infants and children under 5 years of age.
• Represents leading cause of acquired pediatric heart disease in developed nations.
• Carries 20-25% risk of coronary artery abnormalities if left untreated.
• Treatment with intravenous immunoglobulin reduces coronary risk to <5%.
• Demonstrates highest incidence in northeast Asian countries including Japan, South Korea, and Taiwan.
• Exhibits male predominance.

Etiology And Pathogenesis

Etiological Factors

• Exact pathogenesis remains completely unknown.
• Presumed infectious trigger in genetically susceptible hosts.
• Infrequent occurrence in infants <3 months implies protective maternal antibodies.
• Rare in adults implies prior exposure yielding immunity.
• Bacterial superantigen toxin theory proposed due to similarities with toxic shock syndrome.
• Demonstrates selective expansion of Vbeta2 and Vbeta8.1 T cells.

Genetic Susceptibility

• Higher susceptibility documented in Asian and Pacific Islander descent.
• Concordance rate among identical twins approaches 13%.
• Linkage studies identify significant associations with polymorphisms in ITPKC, CASP3, BLK, and FCGR2A genes.
• Specific human leukocyte antigen region alleles influence disease risk.

Vascular Pathology

• Panvasculitis predominantly affects medium-sized muscular arteries.
• Primarily targets coronary arteries, but may involve axillary, subclavian, and iliac arteries.
• Arteriopathy progresses through three distinct histological phases.
  • Phase 1 involves neutrophilic necrotizing arteritis occurring in first 2 weeks. Moves from endothelium through coronary wall. Yields saccular aneurysms.
  • Phase 2 involves subacute/chronic vasculitis lasting weeks to years. Driven by lymphocytes, plasma cells, and eosinophils. Yields fusiform aneurysms.
  • Phase 3 involves smooth muscle myofibroblast proliferation. Results in progressive luminal stenosis and occlusive thrombosis.

Clinical Manifestations

Disease Phases

• Acute febrile phase lasts 1-2 weeks. Characterized by unremitting fever and principal acute signs.
• Subacute phase lasts up to 3 weeks. Characterized by periungual desquamation, marked thrombocytosis, and highest risk of sudden death from aneurysms.
• Convalescent phase begins when clinical signs resolve. Continues until erythrocyte sedimentation rate normalizes at 6-8 weeks.

Classic Diagnostic Criteria

• Diagnosis remains purely clinical. Lacks pathognomonic diagnostic test.
• Standard diagnosis requires fever lasting >= 5 days and 4 out of 5 principal clinical features.
• Experienced clinicians may establish diagnosis after 3 or 4 days of fever.

Non-Cardiac Manifestations

• Musculoskeletal: Arthritis or arthralgia involving small or large joints.
• Gastrointestinal: Unexplained vomiting, diarrhea, severe abdominal pain. Hydrops of gallbladder presents as upper abdominal mass. Mild hepatitis and transaminitis occur.
• Neurological: Extreme irritability prominent in infants. Aseptic meningitis yields cerebrospinal fluid pleocytosis. Transient sensorineural hearing loss. Rare facial nerve palsy.
• Renal/Genitourinary: Sterile pyuria, urethritis, meatitis. Acute renal failure represents rare complication.
• Dermatological: Perianal erythema and desquamation. Reactivation erythema and induration at bacillus Calmette-Guerin inoculation site.

Algorithmic Approach

graph TD
    %% Clinical Presentation
    Start[Patient Presentation: Fever >= 5 days - conventional or <br> >=4 days as per AHA 2024 statement] --> ClinicalCheck{Has >= 4 of 5 Principal Clinical Features?}
    
    %% Classic KD Path
    ClinicalCheck -- Yes --> ClassicKD[Classic Kawasaki Disease Diagnosis]
    ClassicKD --> InitialTx
    
    %% Incomplete KD Path
    ClinicalCheck -- No --> SuspectIncomplete[Suspect Incomplete KD: Prolonged unexplained fever]
    SuspectIncomplete --> LabCheck{CRP >= 3.0 mg/dL OR ESR >= 40 mm/hr?}
    
    LabCheck -- Yes --> SuppCriteria{Has >= 3 Supplemental Lab Criteria <br/> OR Positive Echocardiographic Criteria?}
    LabCheck -- No --> Reevaluate[Re-evaluate or Seek Alternative Diagnosis]
    
    SuppCriteria -- Yes --> IncompleteKD[Incomplete Kawasaki Disease Diagnosis]
    SuppCriteria -- No --> Reevaluate
    IncompleteKD --> InitialTx
    
    %% Initial Management
    InitialTx[Initial Therapy within 10 days:<br/>IVIG 2 g/kg + Low-dose Aspirin 3-5 mg/kg/day] --> HighRiskCheck{High Risk Profile? <br/>Z score >= 2.5, age < 6 months, high Kobayashi}
    
    HighRiskCheck -- Yes --> IntensifiedTx[Intensification Therapy:<br/>Add Corticosteroids, Infliximab, or Statins]
    HighRiskCheck -- No --> MonitorResponse[Monitor Clinical Response]
    IntensifiedTx --> MonitorResponse
    
    %% Assess IVIG Response
    MonitorResponse --> FeverResolution{Persistent/Recrudescent fever <br/> 36h post-IVIG?}
    
    FeverResolution -- Yes --> IVIGResist[IVIG Resistance Diagnosis]
    IVIGResist --> RescueTx[Rescue Therapy:<br/>2nd IVIG, Corticosteroid pulse, Biologics, or Refractory Meds]
    RescueTx --> FollowUp
    
    FeverResolution -- No --> Convalescent[Convalescent Phase]
    Convalescent --> ContAspirin[Continue Aspirin 3-5 mg/kg/day for 6-8 weeks minimum]
    ContAspirin --> FollowUp
    
    %% Long-term Follow-up & Risk Stratification
    FollowUp[Echocardiography Risk Stratification <br/> Baseline, 1-2 weeks, 6-8 weeks] --> ZScores
    ZScores --> Z1[Level 1 & 2: Z score < 2.5 <br/> Discharge at 12 months if normal]
    ZScores --> Z3[Level 3: 2.5 <= Z score < 5 <br/> Annual Echocardiogram]
    ZScores --> Z4[Level 4: 5 <= Z score < 10 <br/> Annual Echo + Stress Imaging, Aspirin +/- Clopidogrel]
    ZScores --> Z5[Level 5: Z score >= 10 <br/> Echo q6mo + Advanced Imaging, Dual Antiplatelet + Anticoagulation]

Incomplete And Atypical Kawasaki Disease

• Manifests prolonged unexplained fever with fewer than 4 principal clinical features.
• Most common in infants <6 months of age.
• Carries highest risk for developing coronary artery abnormalities due to delayed diagnosis.
• Demands high Index graphic algorithms.

Laboratory Criteria For Incomplete KD

• Considered when C-reactive protein >= 3.0 mg/dL or erythrocyte sedimentation rate >= 40 mm/hr.
• Requires >= 3 of the following 6 supplemental criteria:
  • Anemia for age.
  • Platelet count >= 450,000/mm3 after 7th day of fever.
  • Serum albumin <= 3.0 g/dL.
  • Elevated alanine aminotransferase.
  • White blood cell count >= 15,000/mm3.
  • Urine white blood cells >= 10/hpf.

Echocardiographic Criteria For Incomplete KD

• Positive echocardiogram establishes diagnosis if ANY of 3 conditions met:
  • Z score of left anterior descending or right coronary artery >= 2.5.
  • Coronary artery aneurysm directly observed.
  • Presence of >= 3 suggestive features: decreased left ventricular function, mitral regurgitation, pericardial effusion, perivascular brightness, lack of vessel tapering, or Z scores in LAD/RCA between 2 and 2.5.

Kawasaki Disease Shock Syndrome

• Constitutes rare, severe illness manifestation.
• Presents with vasodilatory cardiogenic shock, severe hypotension, and poor systemic perfusion.
• Characterized by markedly elevated C-reactive protein, severe hypoalbuminemia, and profound thrombocytopenia.
• Carries significantly increased risk for intravenous immunoglobulin resistance and giant coronary artery aneurysms.
• Demands immediate intensification of anti-inflammatory therapy and inotropic support.

Investigations And Biomarkers

• Complete blood count reveals leukocytosis with neutrophilia and immature forms.
• Normocytic normochromic anemia frequently present.
• Thrombocytosis occurs typically in second week, occasionally exceeding 1,000,000/mm3.
• Acute phase reactants (erythrocyte sedimentation rate, C-reactive protein) universally elevated during acute phase.
• Elevated N-terminal pro-B-type natriuretic peptide (>500 pg/mL) assists in ambiguous diagnostic cases.
• Neck ultrasonography for lymphadenopathy classically reveals multiple enlarged nodes. Nodes are uniformly hypoechoic with absent necrosis and well-circumscribed margins (cluster of grapes appearance).

Cardiovascular Imaging And Risk Stratification

• Echocardiography serves as primary, noninvasive imaging modality.
• Mandates highest-frequency transducer and accurate body surface area calculation.
• Requires baseline imaging at diagnosis, repeat at 1-2 weeks, and final acute assessment at 6-8 weeks.
• Quantitative Z scores (dimension adjusted for body surface area) of RCA or LAD dictate long-term management and risk.

Acute Medical Management

Standard Initial Therapy

• Goal involves rapid reduction of systemic inflammation to prevent coronary artery damage.
• Therapy mandates initiation within 10 days of fever onset, but indicated later if systemic inflammation persists.

Intensification Therapy For High-Risk Patients

• Strongly indicated for baseline RCA/LAD Z score >= 2.5, infants <6 months, or high Kobayashi risk score¹.
  • Corticosteroids: Intravenous methylprednisolone 2 mg/kg/day divided every 12 hours. Tapered slowly over 2-4 weeks.
  • Infliximab: Monoclonal tumor necrosis factor-alpha antibody. Dose updated to 10 mg/kg intravenously given over 2 hours.
  • Statins (Atorvastatin): Administered in older children to improve endothelial homeostasis and reduce oxidative stress.

Management Of Intravenous Immunoglobulin Resistance

• Defined as persistent or recrudescent fever 36 hours post-initial IVIG completion.
• Occurs in 10-15% of patients. Carries profoundly increased risk for giant coronary aneurysms.
• Second IVIG Infusion: 2 g/kg administered intravenously.
• Corticosteroid Pulse: Intravenous methylprednisolone 30 mg/kg/day for 1-3 consecutive days.
• Biological Agents: Infliximab (10 mg/kg) or Anakinra (Interleukin-1 receptor antagonist).
• Refractory alternatives include Cyclosporine (inhibits calcineurin pathway), Cyclophosphamide, or Plasma Exchange.

Antithrombotic And Anticoagulation Therapy

• Dual approach required for large aneurysms harboring severe risk of luminal thrombosis.
• Small/Medium Aneurysms (Z score < 10): Low-dose aspirin monotherapy. Consider adding Clopidogrel (1 mg/kg/day) for Z score 5-10.
• Giant Aneurysms (Z score >= 10): Mandates dual antiplatelet therapy plus systemic anticoagulation.
• Systemic anticoagulants include Warfarin (target INR 2-3), Low Molecular Weight Heparin, or Direct Oral Anticoagulants (Apixaban, Edoxaban).

Complications And Long-Term Prognosis

Acute Complications

• Macrophage Activation Syndrome: Potentially fatal complication secondary to cytokine storm. Features continuous fever, hepatosplenomegaly, hyperferritinemia (>684 ng/mL), hypofibrinogenemia. Treat with pulse methylprednisolone and Cyclosporine.
• Acute Myocardial Infarction: Risk peaks dramatically during first 2-3 months. Mandates immediate percutaneous coronary intervention or medical thrombolysis (tissue-type plasminogen activator).

Long-Term Outcomes

• Complete regression to normal internal lumen diameter occurs in 50% of small to medium aneurysms over 1-2 years.
• Regressed aneurysms maintain myointimal thickening and abnormal vascular reactivity.
• Giant aneurysms rarely regress and carry indefinite lifetime risk of ischemia, stenosis, and thrombosis.
• Advanced surveillance utilizing Computed Tomography Angiography or Magnetic Resonance Angiography required annually for large/giant aneurysms.
• Surgical revascularization (coronary artery bypass grafting utilizing arterial grafts) indicated for severe reversible ischemia and complex stenosis.
• Structured health care transition to adult cardiology remains paramount for lifelong surveillance and cardiovascular risk factor management.